

# Lookbook

# 2023



BIOTOOLS  
INNOVATOR

## High-throughput, microfluidic enabled platforms for at-line and inline mass spectrometry

Atlanta, Georgia | [andsonbiotech.com](https://andsonbiotech.com)

Andson Biotech's novel microfluidics solution (DynaCHIP) and advanced bioanalytics system (DynaMARK) unlock the full potential of mass spectrometry for modern biotherapeutics like cell and gene therapies and monoclonal antibodies (mAbs). Andson's innovative platforms seamlessly integrate with any mass spec (the gold standard in molecular analysis) to eliminate critical bottlenecks in the discovery, development, and scaling of biotech and pharma processes.

Andson's hardware solution, the DynaCHIP, attaches to the front of existing mass spectrometers to dramatically accelerate the sample preparation process of common workflows from hours to seconds. DynaCHIP leverages state-of-the-art microfluidics that integrate nanoscale tangential flow filtration and microdialysis.

Building upon the DynaCHIP platform, Andson's next product in development, DynaMARK, integrates a machine learning-based software module that generates on-demand measurements for real-time predictive process control and deeper insights into the most critical metrics for modern biopharma workflows.

Andson's platforms facilitate the following disruptive advancements:

1. 1000% increase in productivity: mass spec results in minutes vs hours to days
2. 50% reduction in manufacturing costs: new assays for optimizing and controlling raw-materials usage
3. In-process mass-spec: dynamic measurements to discover new drugs and monitor complex manufacturing processes

Andson is deploying DynaCHIP and piloting DynaMARK with early adopters to significantly enhance the speed and efficiency of biotherapeutic workflows from lab-to-market. Our customers include leading pharma and biotech companies, CROs, and even physician scientists creating new cell therapies that together represent over a \$5B market opportunity.

**Development Stage**

Beta

**Total Equity Funding**

0.8 million

**Seeking**

Seed - 2.5 million

**Mason Chilmonczyk**  
CEO & Co-founder

**Andrei Fedorov**  
Advisor & Co-founder





NanoEX is a next-gen exosome isolation platform that fundamentally addresses all existing issues

Pleasanton, California | [aopia.bio.com](http://aopia.bio.com)

Exosomes hold tremendous potential in early disease detection, precision medicine, and therapeutic/cosmetic agent delivery. However, all the existing exosome isolation technologies still suffer from issues such as low yield, low purity, excessive dilution, and low processing capacity.

NanoEX is a fully automated exosome isolation device that fundamentally addresses all the above problems. It is based on a patented Asymmetric Nanopore Membrane (ANM) technology, which includes high precision and low-cost fabrication of ultrafiltration nanomembranes with conic nanopores, innovative filtration chamber designs, and tangential flow assisted filtration. When applied to exosome isolation, NanoEX can allow highly efficient contaminant removal and exosome retention at 10 times lower filtration pressure than traditional ultrafiltration, which prevents exosome lysis and fusion or protein aggregation. Compared to all existing technologies, ANM can achieve 5 times higher yield and 10 times less protein contamination. Moreover, ANM can enrich exosomes by factors of >20 from conditioned cell culture media, a common sample type used for therapeutic exosome production, and can reach processing volumes of >10L. Therefore, the ANM not only represents a next-generation exosome isolation platform, but also the only technology that allows efficient production of therapeutic grade exosomes.

**Development Stage**      **Prototype**

**Total Equity Funding**      **3.8 million**

**Seeking**      **Series A - 7 million**

**Nan Su**

CEO & Co-founder

**Yuling Luo**

Chairman & Co-founder

**Hsueh-Chia Chang**

CTO & Co-founder

**Ceming Wang**

Director of Engineering



## Smart nanoparticle platform for a unified next-gen multiomic workflow

### Pasadena, California | Argome

Argome is developing a revolutionary biomolecular platform that empowers researchers and healthcare professionals to fully harness the potential of multiomic data. By utilizing our proprietary technology, Argus™ particles, we address the existing barriers hindering the use of multiomic data in personalized medicine. Currently, measuring DNA, RNA, proteins, and metabolites involves fragmented, costly, and slow methods.

Our Argus™ particles act as a versatile substrate capable of specifically capturing any target molecule in solution. They convert the captured molecule into an amplified or unamplified DNA signal, which can be easily detected using established techniques such as qPCR and NGS, depending on the desired level of multiplexity. These particles are programmable, scalable, and cost-effective, providing a comprehensive solution for genomic, proteomic, and metabolomic measurements.

At Argome, we are not only reimagining multiomics from the ground up but also establishing ourselves as a market-defining, vertically-integrated platform. Through collaborations with research, commercial, and strategic partners, we are actively identifying key applications and co-developing innovative products. Our ultimate goal is to reduce costs and enhance the quality of multiomic measurements, revolutionizing the field of personalized medicine.

**Ashwin Gopinath**  
 CTO & Co-founder

**Nayan Agarwal**  
 Co-founder

**Namita Sarraf**  
 Scientist & Business Development

**Alexandre Guiraud**  
 Business Development

**Development Stage**


Prototype

**Total Equity Funding**

N/A

**Seeking**

Seed - 4 million





AtomScope unlocks the final frontier in structural biology: imaging the position, identity, of every molecule, in 3D, and integrating full-scale next-gen AI / ML computer-aided drug design.

San Francisco, California | [atomnaut.com](https://atomnaut.com)

Atomnaut is nearing the completion of a DARPA SBIR Phase II project, unlocking the final frontier in structural biology by imaging the position and identity of every molecule in 3D. The AtomScope technology achieves this by combining in-situ vitrification and quantum-ionization, to measure the position and identity (time-of-flight mass spectrometry) of every molecule in 3D with up to sub-Å resolution. With imaging speeds of up to 13 million amino acids per hour, AtomScope works efficiently on various sample types, including crystalline or disordered, complexed (e.g., protein-protein, protein-antibody, methylated DNA), or free structures, it's all the same to AtomScope. Computer-aided drug design (CADD) powered by full structure knowledge has been estimated to reduce the total cost of drug R&D by 50%, saving \$1 billion per drug.


As a data company, Atomnaut provides two main services: StaaS (Structures as a Service) offers protein/nucleic acid structure imaging for computer-aided drug design. AtomCraft.com facilitates joint-development drug discovery and development contracts through predictive ML/AI models that utilize proprietary databases. These models cover protein structure conformation, allosteric measurements, RNA/DNA tertiary structures, full hierarchical structure imaging of chromatin (primary, secondary, tertiary/higher-order structures), DNA methylation, and binding site visualizations.

**Development Stage**      **Prototype**

**Total Equity Funding**      **N/A**

**Seeking**      **Seed - 8 million**

**Peter Liddicoat**  
CEO & Founder





Aureka Biotechnologies is developing a best-in-class therapeutic discovery platform that integrates high-throughput, single-cell-based functional screening with AI-based drug design and development.

Laguna Hills, California | [aurekabio.com](http://aurekabio.com)

Aureka Biotechnologies is developing a best-in-class therapeutic discovery platform that integrates high-throughput, single-cell-based functional screening and AI-based drug design and development. Each experiment can interrogate millions of therapeutic candidates and generate large-scale, multi-metric data associated with each candidate with respect to function, binding, and developability. The efficient iteration among design, build, test and learn enables us to develop a pipeline that can exponentially accelerate therapeutic design. By unlocking the design principles of immunity, we can transform the immunotherapeutic design from an empirical and trial-and-error approach to truly rational engineering practice.

The high-throughput bispecific antibody discovery pipeline can rapidly generate large numbers of bispecific antibody candidates for therapeutic applications. The innovation involves the development of a novel screening platform that combines single-cell sorting and high-throughput DNA sequencing to identify candidate antibodies with the desired properties. The system also employs an optimized antibody design and engineering approach, which enhances the stability and manufacturability of the bispecific antibodies.

**Development Stage**      **Prototype**

**Total Equity Funding**      **8 million**

**Seeking**      **Series A - 15 million**

**Weian Zhao**  
CEO & Co-founder

**Edgar Zheng**  
VP AI Drug Design

**Alon Wellner**  
VP Biology

**Hongtao Chen**  
Sr. Director of  
Engineering



Platform assembles and engineers DNA longer than 5kb significantly more efficiently and cost effectively than existing approaches

Los Altos, California | [bacstitchdna.com](http://bacstitchdna.com)

Therapeutic, vaccine, food, and agricultural genetic engineering applications that involve optimization of complex systems including metabolic pathways and gene regulatory networks are driving the need for long synthetic DNAs. BacStitch DNA is developing a novel, low friction, highly scalable, in vivo based platform to engineer long complex DNA and accelerate the Design-Build-Test (DBT) cycle used by genetic engineers.

BacStitch is programming bacteria to efficiently stitch together, shuffle, and barcode DNA libraries. The simple and low cost process can be performed with a multi-channel pipette or highly parallelized with off-the-shelf robotics. The technology is currently building sequence verified constructs 15kb+ in length and shows promise to be able to assemble much longer constructs. Based on feasibility work it also may be able to stitch together challenging DNA sequences significantly better than existing in vitro based cloning methods. The platform is highly composable, enabling easy reuse of DNA inputs reducing cost, time, and waste.

Initially, BacStitch will offer collaborative services centered around providing diverse, directed, arrayed and pooled DNA libraries that enable partners to explore sequence spaces that are hard to access with existing approaches. Longer term BacStitch will commercialize solutions that include reagents and SaaS bioinformatics to enable scientists to integrate the technology with their internal DBT processes.


**Development Stage** Beta

**Total Equity Funding** 0.1 million

**Seeking** Seed - 2 million

**David Craford**  
CEO & Co-founder

**Sasha Levy**  
CSO & Co-founder





Enabling Researchers to Fully Realize the Power of 3D Multicellular Models in their biological discovery and therapeutic workflow.

Albuquerque, New Mexico | [bennubio.com](https://bennubio.com)

Traditional 2D cell models are often not predictive of human biology, which is a major reason for the high drug development failure rates. Advances in cell biology and personalized medicine in recent years have led to the development of multicellular 3D models that more faithfully mimic human tissues and tumors. However, the technology to analyze large numbers of intact 3D models rapidly and easily has lagged biological model development. Most current analytical tools were not designed for 3D analysis resulting in significant customer pain points.

By re-imagining 3D multicellular analysis, BennuBio's Velocyt technology transforms flow-based large particle imaging. Incorporating flexibility in experimental design, a simplified workflow, and full sample return, the Velocyt unlocks your valuable biological insights by generating more data per sample saving time and money. Are you basing your research conclusions by measuring only a few 3D cell particles? By delivering unparalleled statistical confidence in your data through the rapid analysis of hundreds to thousands of 3D particles in less than five minutes, the Velocyt directly addresses the challenges in 3D culture variability.

Purposed built for 3D analysis the Velocyt accelerates cutting-edge biological research to maximize patient impact.

**John O'Rourke**  
CEO & President

**Travis Woods**  
COO & Co-founder

**Steve McKernan**  
CFO

**Steve Graves**  
Director of Technology  
& Co-founder

**Development Stage**    **Beta**

**Total Equity Funding**    **9.03 million**

**Seeking**    **Series B - 5 million**





The operating system for Biotechnology companies. An end to end AI powered data platform for biology

Binyamina, Israel | [bioraptor.ai](https://bioraptor.ai)

BioRaptor is a leading provider of AI-powered analytics platforms designed for biotechnology companies. Our cloud-based platform is engineered to streamline the product research and development process by delivering actionable insights that help our customers accelerate their research velocity.

We boast advanced AI and machine learning capabilities, ensuring that our clients achieve more learnings per experiment and reach their goals faster while conducting fewer experiments. Performing the right experiments saves time and money while improving product quality.

Our goal is to empower every scientist and biotech firm, making AI-powered insights a natural part of every workflow. From alt-protein foods to new biopharmaceuticals, BioRaptor will make it easier, quicker, and more cost-effective for scientists to discover, develop, and scale processes that get much-needed food and pharma products into the hands of those who need them.

Our platform is already trusted by top players in the biotechnology market, particularly in precision fermentation and cell culture fields.

**Ori Zakin**

CEO & Co-founder

**Yaron David**

CTO & Co-founder

**Development Stage**


**Beta**

**Total Equity Funding**

**3 million**

**Seeking**

**3 million**



CRISPR Analytics Platform empowers scientists with the knowledge to control and predict gene editing.

San Diego, California | [crisprqc.com](https://crisprqc.com)

CRISPR allows us to modify organisms however we see fit; as a result, companies have rushed to develop cures for diseases that were previously incurable and agricultural products with valuable features. However, control of CRISPR is elusive as it sometimes edits in the wrong place or doesn't work at all; slowing product development and particularly in therapeutic cases is enormously risky. We bring the ability to understand the gene editing process and how it changes, and can use ML to recommend optimizations whether it's product development or even optimization to a patient's unique genome.

CRISPR Analytics Platform measures the entire range of gene editing activity, starting with a customer's chemistry and measuring how it cleaves on the target DNA in real-time. This allows for changing conditions that companies might experience such as variant cell environments, different reagents, different target DNA, and see how this affects the gene editing outcome and gives pathways for optimization. As a purely in vitro system that mimics and correlates to the editing cell editing outcome, this allows customers to understand and control their editing in a much cheaper and more comprehensive way than thousands of cell editing assays. Instead, customers go to cell editing armed with the knowledge of how to control and gain a predictable result every time.

**Development Stage**    **Paying Customers**


**Total Equity Funding**    **1.6 million**

**Seeking**    **Conventional Debt - 2 million | Series A - 20 million**

**Ross Bundy**  
CEO, Co-founder

**Ken Dickerson**  
CRISPR Group Lead

**Kiana Aran**  
Board Member, Co-founder



We develop, market & sell instruments for more effective engineered cell therapies

Berkeley, California | [indeelabs.com](https://indeelabs.com)

Engineered cell therapies (ECTs) are more effective than traditional approaches improving patient outcomes. Today, there is no affordable or practical way to develop and manufacture engineered cell therapies at scale.

ECTs are typically manufactured using lenti- and retroviral transduction, which can cost >\$100M just to develop an asset; can come with year-long wait times; and significant safety risks due to random integration. Alternatively, electroporation can be used for delivery, however, it kills most cells and adversely affects cell function limiting ECT efficacy.

Together, these problems mean there is an unmet need for a gentle, affordable, compact and easy-to-use like Hydropore.

Indee Labs markets and sells Hydropore Research Use Only (RUO) instruments and consumables. The team was recently awarded a \$2M contract from the National Cancer Institute to develop and launch Hydropore Cell Therapy (CT).

Hydropore is a simple, scalable, compact and gentle platform that has been shown to (1) reduce perturbation and (2) improve the function of genome edited chimeric antigen receptor T cells and regulatory T cells in vitro all while being able to (3) process millions to tens of millions of cells in seconds. Hydropore also utilizes commercial or off-the-shelf GMP-grade buffers.

Hydropore RUO is being sold to early access customers such as academics (ie. Stanford, UCSF and MUSC), biotechs and pharma among others. Hydropore CT is in development.

**Development Stage** Paying Customers

**Total Equity Funding** 5.14 million

**Seeking** Series A - 9 million

**Ryan Pawell**  
CEO



Kilobaser is on a mission to decentralize the pharmaceutical industry by providing fully automated desktop nucleic acid synthesis devices

San Francisco, California | [kilobaser.com](https://kilobaser.com)

Life science research and pharma depends on nucleic acid synthesis service providers, making workflows slow and vulnerable.

We have developed a microfluidic nucleic acid synthesis chip that is 100 times more reagent efficient than the industry standard. Our first product, Kilobaser One, is the first microfluidic chip-based desktop synthesizer - not only highly efficient, but also so simple thanks to our reagent cartridge technology that anyone can now synthesize DNA and RNA. Customers around the world use it to develop diagnostics, therapeutics and vaccines.

**Alexander Murer**  
CEO

**Development Stage**    **Paying Customers**

**Total Equity Funding**    **5 million**

**Seeking**    **Series A - 15 million**



Limula offers an automated tool for scalable cell therapy manufacturing.

Lausanne, Switzerland | [limula.ch](https://limula.ch)

The future of Cell and Gene Therapy is automated – Cell & Gene Therapies are ‘living drugs’ made from the patient’s own cells, reprogrammed to target the root of the disease rather than addressing its symptoms. For the first time in history, medicine offers a cure for cancer and other life-threatening conditions. Unfortunately, these personalised treatments are so expensive and difficult to make in large quantities that the global manufacturing capacity cannot provide a cure to every eligible patient. Using closed systems to replace manual methods and standardise the manufacturing of revolutionary cancer treatments is the only way to scale their production and unlock their transformative potential. At Limula, we believe there is a future where everyone should be treated with the most advanced therapies available, at reasonable cost, wherever they are.

Limula provides an automated tool for scalable cell therapy manufacturing – It is a unique innovative solution that combines a bioreactor and a centrifuge into one device, for the first time. It leverages the exceptional cell processing capabilities of the technology to perform every step of gene edited cell therapy production in a single device. The precious cells stay in the same container during the entire manufacturing. The platform is composed of a mechatronic device for process automation, and a single-use consumable containing the core bioreactor technology with integrated process analytics. It is perfectly suited for the ‘one patient – one batch’ production of personalised treatments with minimal human intervention.

Swiss Made engineering meets cell therapy – Limula is a Life Science tool company based in Lausanne, Switzerland, thriving in this ecosystem by tapping into the country’s long tradition of Pharma and Biotech, exceptional engineering and life science talent pool and world-class infrastructure and research institutions.

**Development Stage**    **Beta**


**Total Equity Funding**    **0.5 million**

**Seeking**    **Seed - 4.5 million**

**Luc Henry**  
CEO

**Yann Pierson**  
CTO

**Thomas Eaton**  
COO





We develop low-cost & large-scale production processes for bioactive peptides & proteins

Bavaria, Germany | [mk2.bio](https://mk2.bio)

Peptides, which are short proteins, have an enormous potential to be applied as sustainable, natural and target-specific nutraceuticals and metabolic engineers. Example applications are milk-derived antimicrobial peptides, fungicides for hydroculture, pesticide-like peptides against parasites like the salmon louse, and particularly growth factors in cultured meat production. However, conventional synthesis technologies are not capable to meet the required technical specifications and/or cannot be sufficiently scaled-up, so that synthesis cost is too high for a comprehensive peptide utilization - despite their great potential.

Peptides and proteins have an enormous potential to be utilized as active agents in several mass segments such as the cosmetics, F&B, animal health, and agriculture. Particularly mid-length products with 15-300 amino acids are extremely promising from the technical point of view. However, no technology was capable of producing & providing the required products at sufficiently large scale while simultaneously bringing down the production cost by several orders of magnitude – both are essential for industrial applications.


mk2 Biotechnologies developed a synthesis platform that enables the synthesis of the required peptides, that can be fully scaled up, and that does not require any expensive or toxic materials. The result is a platform, that for the first time can solve the customer problem by providing cost-efficient, high-purity peptides & proteins at large scales.

**Development Stage** Beta

**Total Equity Funding** 2 million

**Seeking** Series A - 10 million

**Konstantinos Antonopoulos**  
Managing Director



PAK BioSolutions provides automated systems for continuous purification of biopharmaceuticals that provide 4X productivity improvements

Vienna, Virginia | [pakbiosolutions.com](http://pakbiosolutions.com)

Existing biopharmaceutical manufacturing facilities and processes are expensive, unproductive and have poor space utilization. Henry Ford began using the assembly line in the automotive industry in 1913. Yet the biopharmaceutical industry still operates in batch mode, completing approximately one process step per day over 5-10 days and finishing one batch before starting the next. Continuous purification technologies recently introduced by PAK and others have the opportunity to change this paradigm.

PAK BioSolutions aims to scale up their continuous biopharmaceutical manufacturing technologies to enable rapid deployment of life-saving vaccines and therapeutics world-wide at rates not currently attainable. PAK's pilot scale automated purification system, currently on the market, is leading the biopharmaceutical industries efforts to move to continuous manufacturing. With continuous manufacturing, all stages of the manufacturing process are operated in series simultaneously, similar to the assembly line. This mode of operation reduces manufacturing footprint by 75% and is 4X more productive than the traditional batch approach where one step is performed at a time.

The PAK systems novel design allows operation of up to four steps in series, simultaneously, in the same system. Multiple systems can be connected in series to perform an entire purification process. These steps may consist of chromatography, filtration, virus inactivation and ultrafiltration/diafiltration. While other setups on the market require supervisory controls in addition to five individual purification systems, only two PAK systems and no additional control architecture are required, greatly reducing capital investment and design time by the customer. The "out of the box" concept coupled with an aesthetically simple interface makes the PAK system easy to order, easy to install, and easy to operate.

**Development Stage**

**Paying Customers**

**Total Equity Funding**

**0.476 million**

**Seeking**

**Series A - 8 million**

**Joanna Pezzini**  
CEO



Remove variability from your biomanufacturing process with ReelReactor, a compact continuous flow device that improves product quality and minimizes costs.

Encinitas, California | [reelreactor.com](https://reelreactor.com)

Mixing chemicals or biological liquids, and allowing them to react for precise durations, may seem straightforward in theory, but executing this process in a manufacturing setting is challenging. Consider a biomanufacturing company aiming to perform one of these simple reactions. They have two options: batch production or continuous production using continuous stirred-tank reactors. Unfortunately, batch production falls short due to inconsistent product quality, higher costs, and limited scalability. On the other hand, continuous stirred-tank reactors, while providing continuous production, struggle to precisely control residence times, resulting in under-reacted and over-reacted product mixtures.

Enter ReelReactor, a game-changing solution designed to bridge this technological gap. Tailored for life science applications, ReelReactor ensures a continuous and consistent high-quality product with precise residence times, streamlining quality control. Not only does it offer scalability and minimal operational overhead, but it also employs a sterile single-use consumable that minimizes downtime.


ReelReactor achieves these results by revolutionizing continuous reactions. Liquid ingredients are pumped into a long tube at specific ratios, where they formulate and mix. Immediately after mixing, the reactor performs external manipulation on the tube, transforming the continuous liquid flow into many isolated subunits. Each subunit remains isolated until its reaction is complete, at which point the reactor sequentially releases it to the next step of the workflow. Every drop of product released by ReelReactor will have experienced identical residence times, ensuring unparalleled consistency.

**Mike Gordon**  
CEO

**Development Stage**    **Prototype**

**Total Equity Funding**    **0.11 million**

**Seeking**    **Seed - 0.75 million**



## Benchtop platform enabling cell-based therapeutic discovery with unprecedented precision and scale

San Francisco, California | [scribebiosciences.com](https://scribebiosciences.com)

The discovery of cell therapy and therapeutic antibody candidates is limited by cell-based assay workflows that are slow and imprecise. Characterizing cell interactions on the single-cell scale is of particular importance in the immunotherapy field and is not currently possible at high throughput.

The performance of cell- and antibody-based therapies is often dependent on therapeutic modification of cell-cell interactions, yet standard methods are not appropriate for the detection of rare and important therapeutic candidates. Scribe Biosciences is commercializing a new paradigm in cell interaction profiling, deemed Microenvironment on Demand (MOD), to enable the construction of precision functional single-cell assays with unprecedented precision and scale. MOD leverages high throughput droplet microfluidic sorting and combining to construct multicellular combinations in a deterministic process that allows the inclusion of programmed reagent mixtures and beads.

This technology is being commercialized as a flexible benchtop research instrument with recurring revenue in the form of disposables and reagents. MOD will enable multi-step workflows that include multiple rounds of functional assay construction and on-chip single-cell sequencing prep to provide a robust solution for therapeutic researchers.


**Russell Cole**  
CEO

**Ian Walton**  
Sr. VP of Engineering

**Development Stage** Prototype

**Total Equity Funding** 6 million

**Seeking** Series A - 20 million



## Benchtop DNA printer with unparalleled reproducibility and scalability

Santa Cruz, California | [switchbacksys.com](https://switchbacksys.com)

Extensive Voice of Customer has revealed a subset of researchers that are dissatisfied with current synthetic DNA offerings from service providers. We refer to these customers as “pioneers”. They are using DNA as a fundamental discovery tool in their research. Currently, these scientists are burdened by (1) slow turnaround times from service providers, (2) the inability to manage and control bottlenecks in their research, and (3) a fear of sharing confidential sequence information with outside vendors. The few benchtop DNA printers that exist today are difficult to use and maintain, are not cost-effective, and have extremely limited throughput.

Switchback Systems is developing a revolutionary DNA printer. It is a plug-and-play system with a small benchtop footprint. Our novel approach to both the system and the chemistry achieves:

- Quality - with a reliable in-line QC that generates a quality score for every DNA product
- Privacy & ease of use - keeping sequences confidential along with a quick set-up and no chemical handling
- Throughput - >96 oligos per run
- Competitive pricing - comparable to service providers
- Flexibility - different oligo products on the same platform

**Mary Noé**

CEO & Co-founder

**Amy Hiddenson**

CTO

**Ariel Notcovich**

VP of Product Development

**Development Stage**    **Prototype**

**Total Equity Funding**    **6 million**

**Seeking**    **Series A - 8 - 10 million**





Platform to characterize temporal cell functions with game changing scale, scope and data integrity

Caesarea, Israel | [teracyte.ai](https://teracyte.ai)

Biology is all about cell functions, how cells behave, and particularly how they respond to stimuli or treatment. Currently, there are no tools that enable the collection of dynamic data about cell functions on the scale and data integrity required for big-data applications. Capturing cell function at scale, enables characterization of heterogenous samples with unprecedented depth, addressing a major need in the cell therapy market for robust batch characterization and clinical efficacy predictions. Looking ahead, utilizing the unique data modality generated by our platform to build computational models, opens up possibilities for the next generation of predictions across the drug development cycle. From compound MoA to functional patient stratification.

Our platform provides a comprehensive solution, that allows for high throughput and robust fluorescence, brightfield, and luminescence measurements of live cells over time. Cells are captured and maintained in proprietary silicon cell arrays and each array is embedded in a proprietary perfusion chamber allowing users to monitor and control experimental conditions. the chambers are then placed in our automated imaging system which continuously collects high-resolution reflective microscopy images coupled with extremally sensitive fluorescent images. the images are processed by dedicated software which extracts single-cell information that is rigorously standardized and normalized.

The raw data annotated data, and metadata are then stacked and organized on the cloud, optimizing accessibility for visualization, QA, and analysis. Finally, our team of world-class data scientists is building unique AI tools based on our novel data modality with numerous applications along the drug discovery and development value chain.


**Development Stage** Beta

**Total Equity Funding** 1.13 million

**Seeking** Seed - 7.5 million

**Yoav Nissan-Cohen**  
CEO

**Gal Lenz**  
CTO





Simple, rapid organoid sample preparation kit for patient-derived cancer organoids (PDCOs) and life science applications

Los Angeles, California | Entropic Biosciences Inc.

Entropic Biosciences Inc. has designed a proprietary chemically defined cell culture coating technology that enables the growth of high-throughput, automated, self-standing 3D cellular organoids. The biomaterial activates an anchorage-dependent mechanotransduction pathway that is universally present in eukaryotic cells. We have generated healthy viable organoids from primary cell types that competitors are not able to achieve. Our coating demonstrates unprecedented organoid generation needing less than a day in culture. This technology will allow for rapid access to 3D models derived from individual patients' cancers for drug screening capabilities in which tumors are recapitulated in vitro, enabling a precision medicine approach to test potential chemotherapeutics.

**Amir Nasajpour**  
Founder

**Development Stage** Minimal Viable Product

**Total Equity Funding** 0

**Seeking** Pre-seed – \$700,000

